Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
A high proliferation rate of malignant cells requires an increased energy production, both by anaerobic glucose metabolism and mitochondrial respiration. Moreover, increased levels of mitochondria-produced reactive oxygen species (ROS) promote survival of transformed cells and contribute to the disease progression both in solid tumors and leukemia. Consequently, interfering with mitochondrial metabolism has been used as a strategy to specifically target leukemic cells. SAM50 is a mitochondrial outer membrane protein involved in the formation of mitochondrial intermembrane space bridging (MIB) complex. Although the importance of SAM50 in maintaining MIB integrity and in the assembly of mitochondrial respiratory chain complexes has been described, its specific role in the normal and leukemic hematopoietic cells remains unknown. We observed that human leukemic cells display a specific dependency on SAM50 expression, as downregulation of SAM50 in BCR-ABL-expressing, but not normal CD34(+) human hematopoietic stem and progenitor cells (HSPCs) caused a significant decrease in growth, colony formation, and replating capacity. Mitochondrial functions of BCR-ABL-expressing HSPCs were compromised, as seen by a decreased mitochondrial membrane potential and respiration. This effect of SAM50 downregulation was recapitulated in normal HSPCs exposed to cytokine-rich culture conditions that stimulate proliferation. Both oncogene-transduced and cytokine-stimulated HSPCs showed increased mitochondrial membrane potential and increased ROS levels compared to their normal counterparts. Therefore, we postulate that human leukemic HSPCs are highly dependent on the proper functioning of mitochondria and that disruption of mitochondrial integrity may aid in targeting leukemic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RAC2 interacts with SAM50, a mitochondrial transporter involved in the regulation of mitochondrial membrane potential and ROS production:36,37”
From A gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency (2020) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment
Schafer, Z. T., Grassian, A. R., Song, L., Jiang, Z., Gerhart-Hines, Z., Irie, H. Y., Gao, S., Puigserver, P., & Brugge, J. S. (2009) · Nature · doi:10.1038/nature08268 · Cited by 1,031 · cited 1×
“Cancer cells counteract the overproduction of ROS by upregulating the antioxidant systems to prevent ROS-induced macromolecule damage, senescence, and apoptosis induction [8–11].”
HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523
Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2004) · Blood · doi:10.1182/blood-2004-05-1941 · Cited by 278
Schuringa, J. J., Chung, K. Y., Morrone, G., & Moore, M. A. S. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041024 · Cited by 140 · cited 1×
“CFC assays were performed as previously described [35].”
Self-citationMitochondrial regulation of oxygen sensing
Bell, E. L., Emerling, B. M., & Chandel, N. S. (2005) · Mitochondrion · doi:10.1016/j.mito.2005.06.005 · Cited by 130
Zamora, M., Meroño, C., Viñas, O., & Mampel, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404928200 · Cited by 96 · cited 1×
“Mitochondrial membrane potential was measured by flow cytometry using hexamethylindodicarbocyanine iodide (DilC1; Life Technologies, Bleiswijk, The Netherlands) as described previously [36].”
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo
Sengupta, A., Arnett, J., Dunn, S., Williams, D. A., & Cancelas, J. A. (2010) · Blood · doi:10.1182/blood-2009-10-247437 · Cited by 52 · cited 1×
“Also, in BCR-ABL-expressing leukemic cells pharmacological inhibition or decreased expression of small GTPase RAC2 selectively targeted leukemic and not normal HSPCs by decreasing their mitochondrial activity and ROS production [29,39,40] (Capala et al.”
Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2
Capala, M. E., Maat, H., Bonardi, F., van den Boom, V., Kuipers, J., Vellenga, E., Giepmans, B. N. G., & Schuringa, J. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128585 · Cited by 20 · cited 6×
“We have identified that RAC2 may be required for the proper functioning of mitochondria due to its direct interaction with mitochondrial transport proteins, such as SAM50 and Metaxin 1 [31].”
InfluentialSelf-citation
Research works printed but not linked: 37
- Racker E, 1972, Am Sci, 60, 56
- 10.1038/nrc3038 · DOI · Paper page
- 10.1085/jgp.8.6.519 · DOI · Paper page
- 10.1042/bj1340707 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-0171 · DOI · Paper page
- 10.1038/sj.leu.2403545 · DOI
- 10.1113/jphysiol.2003.049478 · DOI · Paper page
- 10.1074/jbc.272.1.217 · DOI · Paper page
- 10.1126/science.270.5234.296 · DOI · Paper page
- 10.1038/ncb1807 · DOI · Paper page
- 10.1126/science.1211485 · DOI · Paper page
- 10.1126/science.1215637 · DOI · Paper page
- 10.1016/0009-2797(94)90029-9 · DOI · Paper page
- 10.1016/0891-5849(96)00109-8 · DOI · Paper page
- 10.1093/carcin/20.4.663 · DOI · Paper page
- 10.1152/ajpcell.2000.279.3.C868 · DOI
- 10.1038/nrd2803 · DOI · Paper page
- 10.1007/s11010-008-9920-4 · DOI
- 10.1016/j.cell.2011.02.013 · DOI · Paper page
- 10.1016/j.ccr.2011.10.015 · DOI · Paper page
- 10.3109/10428194.2012.696313 · DOI · Paper page
- 10.1182/blood-2007-05-092510 · DOI · Paper page
- 10.1074/jbc.M002094200 · DOI · Paper page
- 10.1038/leu.2008.78 · DOI
- 10.1038/leu.2009.49 · DOI · Paper page
- 10.1182/blood-2011-10-385658 · DOI · Paper page
- 10.1074/jbc.M413816200 · DOI · Paper page
- 10.1038/sj.embor.7400982 · DOI · Paper page
- 10.1074/jbc.C300442200 · DOI · Paper page
- 10.1128/MCB.06388-11 · DOI · Paper page
- 10.1182/blood-2010-02-270660 · DOI · Paper page
- 10.1182/blood.V99.9.3197 · DOI
- 10.1182/blood-2013-10-532200 · DOI · Paper page
- 10.1371/journal.pone.0111568 · DOI · Paper page
- 10.1038/nrc2981 · DOI · Paper page
- 10.1080/10715760903186132 · DOI
- 10.1189/jlb.0113006 · DOI
Cited by
Lagresle-Peyrou, C., Olichon, A., Sadek, H., Roche, P., Tardy, C., Silva, C. D., Garrigue, A., Fischer, A., Moshous, D., Collette, Y., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.230250 · Cited by 35
Metadata
- Authors
- Capala, M. E., Pruis, M., Vellenga, E., & Schuringa, J. J.
- Affiliations
- Department of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Venue
- Stem Cells and Development
- Publisher
- SAGE Publications
- Published
- 2016-03
- Volume
- 25
- Issue
- 5
- Pages
- 427-437
- ISSN
- 1547-3287
- 1557-8534
- Cited by
- 13
- References
- 8
- Language
- en
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.